durvalumab + daratumumab + pomalidomide + dexamethasone

This is a **combination regimen** comprising four drugs: - **Durvalumab**: a monoclonal antibody immune checkpoint inhibitor targeting PD-L1, primarily used for cancer immunotherapy to block the interaction between PD-L1 and PD-1 or CD80, thus enhancing antitumor immune response. - **Daratumumab**: a monoclonal antibody that targets CD38 on multiple myeloma cells, exhibiting both direct antitumor activity (cell death via complement-dependent cytotoxicity, antibody-dependent cell cytotoxicity, and apoptosis) and immunomodulatory effects (depletion of immunosuppressive cells and enhancing T-cell activity)[2][1]. - **Pomalidomide**: an immunomodulatory imide drug (IMiD) that enhances immune cell function, inhibits angiogenesis, and induces tumor cell apoptosis—it upregulates CD38 and shows synergy with anti-CD38 agents like daratumumab[6][1]. - **Dexamethasone**: a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties; often included to mitigate immune-related adverse effects of other agents and potentiate antineoplastic efficacy. There are **no regulatory approvals or published clinical trials currently identified for the quadruplet combination specifically containing durvalumab + daratumumab + pomalidomide + dexamethasone**. Extensive data are available for the triplet of daratumumab + pomalidomide + dexamethasone in relapsed or refractory multiple myeloma[1][2][3][4][5][7], but durvalumab is not part of these approved or investigated regimens. Durvalumab has been tested in combination regimens for hematologic and solid tumors elsewhere, but not with this exact combination. Thus, its clinical use, mechanisms of synergy, development status, and safety profile as a four-drug regimen are currently **investigational and uncharacterized** according to present literature and regulatory data.